You are here

Novartis

Novartis hits another setback in plan to repurpose rare disease drug in lung cancer

BioPharma Dive

Mon, 10/25/21 - 11:51 pm

clinical trials

Novartis has negotiated Zolgensma access for half of the European SMA population, exec says. How'd it get there?

Fierce Pharma

Fri, 10/22/21 - 12:39 pm

spinal muscular atrophy

Novartis signs new agreement with BioNTech for COVID-19 vaccine fill and finish

Biopharma Reporter

Thu, 10/21/21 - 09:29 am

drug manufacturing

Novartis exec says COVID exposed pharma manufacturing weaknesses. Here's how he plans to fix them

Fierce Pharma

Thu, 10/14/21 - 11:08 am

drug manufacturing

Three generic firms shell out $447M more to settle federal price fixing allegations

Endpoints

Mon, 10/4/21 - 10:59 am

Taro Pharmaceuticals

Novartis tightens up its COVID-19 vaccine policy for staff

Pharmaforum

Sun, 10/3/21 - 08:14 pm

vaccine mandates

A newly private Novartis partner bags a megaround on its first go to turbocharge CAR-T, cell therapy pipeline

Endpoints

Thu, 09/30/21 - 11:04 am

Cellular Biomedicine

Novartis drug raises hope of tackling malaria drug resistance

Pharmaforum

Thu, 09/30/21 - 10:49 am

Oncology the focus for big pharma catalysts

EP Vantage

Tue, 09/28/21 - 11:19 am

Gilead Sciences

HHS lines up Novartis, Lilly, AstraZeneca and 3 other drugmakers for fines due to drug discount violations

Endpoints

Fri, 09/24/21 - 12:00 pm

United Therapeutics

Novartis reshuffling doesn't portend a pullback from gene therapy, company says

Fierce Pharma

Wed, 09/22/21 - 11:56 am

Novartis acquires Arctos Medical to expand optogenetics portfolio

Biopharma Reporter

Tue, 09/21/21 - 10:50 am

Zolgensma patent spat brews between Novartis and Regenxbio as top Novartis gene therapy exec departs

Endpoints

Mon, 09/20/21 - 11:15 am

Novartis presents new Kisqali data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer

Drugs.com

Sun, 09/19/21 - 11:58 pm

clinical trials

ESMO: Novartis links prostate cancer drug to improved pain, quality of life as regulatory filings near

Fierce Biotech

Thu, 09/16/21 - 11:04 pm

clinical trials

prostate cancer

First FDA filing for Novartis’ latecomer PD-1 drug tislelizumab

Pharmaforum

Mon, 09/13/21 - 10:26 am

esophageal cancer

Sandoz in oncology biosimilar deal with China’s Bio-Thera

Biopharma Reporter

Wed, 09/8/21 - 11:15 am

Bio-Thera Solutions

FDA grants fast track designation for Novartis’ LNA043 to treat osteoarthritis

Pharmaceutical Business Review

Fri, 09/3/21 - 11:01 am

osteoarthritis of the knee

Novartis finalizes deal to make new heart drug widely available in England

BioPharma Dive

Wed, 09/1/21 - 10:55 pm

Versanis Bio unveils $70M and a Novartis drug ready for Phase 2 test in obesity

MedCity News

Tue, 08/31/21 - 10:05 pm

clinical trials

Pages